A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Hydroxychloroquine (Primary) ; Opaganib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 08 Jul 2022 Status changed from active, no longer recruiting to completed.
- 23 Jun 2022 According to a RedHill Biopharma media release, the study analysis expected in Q3/2022.
- 31 Jan 2022 Status changed from recruiting to active, no longer recruiting.